SEC Filing Summary: BioSig Technologies, Inc.
Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on November 3, 2020, reporting events occurring on October 29, 2020. The company is incorporated in Delaware and trades on the NASDAQ Capital Market. The filing addresses Item 5.02 regarding the departure of a director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
On October 29, 2020, Jerome B. Zeldis, M.D., Ph.D., tendered his resignation from the Board of Directors and the nominating and corporate governance committee. The resignation became effective on October 31, 2020. The company explicitly stated that the departure was not in connection with any dispute or disagreement regarding the Company's operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or management commentary regarding future financial performance. No specific risks or contingencies were disclosed in this report other than the standard disclosure of the director's retirement.
Key Facts for Investor Verification
- Jerome B. Zeldis, M.D., Ph.D., resigned from the Board effective October 31, 2020.
- The resignation was voluntary and unrelated to any disputes with the company.
- The filing does not include financial results or updated operational guidance.
- Investors should verify if a replacement director has been appointed in subsequent filings.